by Penny L. Post, PhD and Manon M.J. Cox
Volume 1, Issue 2 (Summer 2002)
Globally, an estimated 36 million people are living with HIV, and some 20 million people have already died of AIDS. Today, there is still no HIV vaccine available. HIV virus-like particles are an attractive vaccine candidate due to their ability to induce both antibody and cytotoxic T-lymphocyte responses. In this article, we describe the development of a production process for an HIV particle vaccine, HIV-1 p55 (gag). The gag precursor protein (p55) is sufficient for assembly and cellular release of retrovirus-like particles. We expressed the p55 gag protein using the BEVS technology in Spodoptera frugiperda expresSF+ cells…
Citation:
Post PL, Cox MMJ. Production of a p55gag Particle Vaccine Using the Baculovirus Expression Vector System Technology. BioProcess J, 2002; 1(2): 52-59.